Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Analysts maintain a “Moderate Buy” consensus on Enliven Therapeutics, with six buy ratings and one sell rating. The average 12-month price target is $72.67, with recent targets ranging from $62 to $82.
• Company insiders sold 190,831 shares worth approximately $11.0 million over the last quarter, including a director’s $9.6 million sale; insiders own 3.0% of the stock.
• ELVN opened at $58.82 after rising 1.3%, near its 52-week high of $62.32, but the company reported a quarterly loss of $0.49 per share—worse than the consensus estimate of $0.39.

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the seven research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 1-year target price among analysts that have covered the stock in the last year is $72.6667.

A number of analysts have recently weighed in on the company. The Goldman Sachs Group raised their target price on Enliven Therapeutics from $67.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of Enliven Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 8th. Stifel Nicolaus increased their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Mizuho raised their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 2nd. Finally, Guggenheim decreased their price objective on Enliven Therapeutics from $80.00 to $78.00 and set a "buy" rating for the company in a research note on Thursday, August 6th.

Insider Buying and Selling

In other news, Director Mika K. Derynck sold 158,795 shares of the firm's stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director owned 87,373 shares of the company's stock, valued at $5,260,728.33. This trade represents a 64.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm's stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total transaction of $316,787.52. Following the sale, the chief financial officer owned 46,054 shares in the company, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 190,831 shares of company stock valued at $10,991,723. 3.00% of the stock is owned by company insiders.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV bought a new stake in Enliven Therapeutics during the first quarter worth $38,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after acquiring an additional 594 shares during the period. BNP Paribas Financial Markets grew its position in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new position in shares of Enliven Therapeutics during the 4th quarter worth about $83,000. Finally, Quantbot Technologies LP increased its stake in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock worth $90,000 after purchasing an additional 1,434 shares during the last quarter. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Trading Up 1.3%

ELVN opened at $58.82 on Friday. The stock has a market cap of $4.31 billion, a PE ratio of -35.22 and a beta of 0.27. Enliven Therapeutics has a 1 year low of $14.78 and a 1 year high of $62.32. The stock's 50 day simple moving average is $50.90 and its 200-day simple moving average is $40.79.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Equities analysts forecast that Enliven Therapeutics will post -1.67 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source